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Diabetic nephropathy (DN) is a major complication associated with both type 1 and
type 2 diabetes, and a leading cause of end-stage renal disease. Conventional
therapeutic strategies are not fully efﬁcacious in the treatment of DN, suggesting an
incomplete understanding of the gene regulation mechanisms involved in its patho-
genesis. Furthermore, evidence from clinical trials has demonstrated a ‘‘metabolic
memory’’ of prior exposure to hyperglycemia that continues to persist despite
subsequent glycemic control. This remains a major challenge in the treatment of DN
and other vascular complications. Epigenetic mechanisms such as DNA methylation,
nucleosomal histone modiﬁcations, and noncoding RNAs control gene expression
through regulation of chromatin structure and function and post-transcriptional
mechanisms without altering the underlying DNA sequence. Emerging evidence
indicates that multiple factors involved in the etiology of diabetes can alter epigenetic
mechanisms and regulate the susceptibility to diabetes complications. Recent studies
have demonstrated the involvement of histone lysine methylation in the regulation of
key ﬁbrotic and inﬂammatory genes related to diabetes complications including DN.
Interestingly, histone lysine methylation persisted in vascular cells even after with-
drawal from the diabetic milieu, demonstrating a potential role of epigenetic
modiﬁcations in metabolic memory. Rapid advances in high-throughput technologies
in the ﬁelds of genomics and epigenomics can lead to the identiﬁcation of genome-
wide alterations in key epigenetic modiﬁcations in vascular and renal cells in diabetes.
Altogether, these ﬁndings can lead to the identiﬁcation of potential predictive
biomarkers and development of novel epigenetic therapies for diabetes and its
associated complications.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Diabetes and metabolic disorders have reached epidemic
proportions worldwide and are major risk factors for several
long-term complications, including progressive renal failure and
chronic kidney disease, termed diabetic nephropathy (DN). More
than 40% of patients with diabetes progress to DN, a major cause
of end-stage renal disease (ESRD). In addition, patients with DN
are more susceptible to macrovascular diseases such asrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
tes, Beckman Research Institu
jan).atherosclerosis, hypertension, and stroke, leading to a higher
mortality rate among diabetic patients with ESRD than among
those without ESRD. DN is pathologically characterized by renal
glomerular hypertrophy, expansion of mesangial and tubular
compartments, accumulation of extracellular matrix in multiple
renal cells, inﬂammatory cell inﬁltration, and podocytopenia
associated with foot process effacement. These factors lead toublished by Elsevier. This is an open access article under the CC BY-NC-
te of City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.
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dysfunction. Clinically, DN is identiﬁed by albuminuria, rising
creatinine levels, and aberrant glomerular ﬁltration rates. Signal
transduction mediated by key factors associated with diabetes,
such as high glucose (HG), advanced glycation end products
(AGEs), oxidized lipids, proinﬂammatory cytokines, and local
growth factors including transforming growth factor-b1 (TGF-b)
and angiotensin II (Ang II), can lead to renal hypertrophy and
ﬁbrosis through various biochemical mechanisms [1–6].
Several treatment strategies are available to cure DN or
reduce its progression. These include modalities used to
suppress the renin–angiotensin–aldosterone system and con-
trol blood glucose levels. However, diabetic patients are still
reaching ESRD at an alarming rate. Moreover, clinical and
experimental studies have shown that the risk and severity of
diabetic complications, including DN, seem to persist even
after glucose normalization, suggesting a ‘‘metabolic mem-
ory’’ of the prior exposure to HG [7,8]. These ﬁndings imply
that the current knowledge based on biochemical mechan-
isms, genetics, and proteomics research [6,9–12] does not
explain the pathophysiology of DN completely. More than a
decade after the human genome has been sequenced, it is
becoming increasingly clear that changes in the DNA
sequence and genetic mutations alone cannot fully explain
the diversity of cellular responses and disease incidence in the
general population. On the other hand, epigenetic mechan-
isms in chromatin can also regulate gene expression, cellular
identity, phenotypic variations, and disease states without
any alterations in the underlying DNA sequence. Epigenetics
can be inﬂuenced profoundly by diet, lifestyle, and the
environment—key factors associated with the etiology of
diabetes [13,14]. Thus, complex interactions between genes
and the environment can play signiﬁcant roles in common
human diseases such as diabetes and related pathologies.
Given the high incidence and debilitating nature of DN, it is
imperative to evaluate additional mediatory factors and
therapeutic targets. The current review focuses on epigenetics
and the emerging evidence for epigenetic mechanisms in
diabetes and its complications, with special emphasis on DN.Epigenetics
The term ‘‘epigenetics’’ originally referred to the pro-
grammed changes during development that cannot be
explained by conventional genetics [15]. Epigenetics typically
refers to changes in gene expression and phenotype, including
those conferred mitotically or meiotically, that occur without
any alterations in the underlying DNA sequence. More recently,
epigenetics is deﬁned as ‘‘the structural adaptation of chromo-
somal regions so as to register, signal, or perpetuate altered
activity states’’ to account for alterations in the chromatin state
[15,16]. Epigenetic signals regulate gene expression through
chromatin remodeling, which in turn regulates chromatin
structure and access to transcription factors and coregulators.
Epigenetic control of gene regulation plays an important role in
embryogenesis, cellular differentiation and development, cell
identity, genomic imprinting, immune cell function, stem cell
plasticity, transcriptional memory, and cellular responses to
environmental signals [17–19]. Poor dietary choices and expo-
sure to environmental pollutants can regulate epigenetic
mechanisms to induce abnormal metabolic phenotypes that
can be further compounded by genetic susceptibility [14,20].Furthermore, environmentally induced epigenetic modiﬁca-
tions could lead to phenotypic changes that persist even long
after the original exposure was removed. Several studies also
demonstrated the transgenerational inheritance of epigenetic
changes, thus highlighting the potential effect of maternal
malnutrition or overnutrition on the fetus that can result in
deleterious effects later in adult life, including predisposition to
diabetes and associated complications [13,21,22]. However,
whether low birth weight increases the risk for DN is still not
clear [23]. Furthermore, while the role of genetic factors
associated with DN has been examined extensively, the role
of epigenetics is only recently being considered.Epigenetic modiﬁcations in chromatin
and the epigenome
Chromatin, the site of epigenetic modiﬁcations in the nucleus,
is composed of chromosomal DNA tightly packaged into repeat-
ing units called nucleosomes. Each nucleosome is made up of 146
bp DNA, which is wrapped around an octamer protein complex
consisting of dimers of core histone proteins H2A, H2B, H3, and
H4 held together by a linker histone H1 [24]. Chromatin structure
is dynamically regulated by epigenetic modiﬁcations between
transcriptionally silent ‘‘heterochromatin’’ and active ‘‘euchroma-
tin’’ states (Fig. 1). These include covalent post-translational
modiﬁcations (PTMs) of nucleosomal histones as well as DNA
methylomes (DNAMes), while noncoding RNAs such as micro-
RNAs can also regulate gene expression by post-transcriptional
epigenetic mechanisms. Epigenetic modiﬁcations provide dock-
ing sites for proteins/enzymes that alter chromatin structure,
remodel nucleosomes, and erase or recruit other transcription
regulators. Combinatorial effects of epigenetic modiﬁcations on
promoters, enhancers, and other regulatory elements of the
genome dictate gene expression patterns and the resultant
phenotypes under normal and pathophysiological conditions
[20,21,25]. Genome-wide patterns of these modiﬁcations collec-
tively form the ‘‘epigenome,’’ which is cell-type speciﬁc, can be
modulated by environmental cues, and can lead to aberrant gene
expression associated with human diseases [13,20,26].
DNAMe, the most highly studied epigenetic modiﬁcation,
generally takes place on cytosines of CpG dinucleotides in
regions known as ‘‘CpG’’ islands located in chromosomal DNA.
DNAMe is catalyzed by DNA methyltransferases (DNMTs) that
transfer methyl group from S-adenosyl-methionine to the 50
position of cytosine (50-methyl cytosine). In mammalian cells,
DNMT3A and DNMT3B mediate de novo methylation while
DNMT1 acts as a maintenance methyl transferase [18]. Pro-
moter DNAMe generally leads to gene silencing via multiple
mechanisms including inhibition of transcription factor bind-
ing, increasing nucleosome occupancy at transcriptional start
sites, regulation of histone PTMs and chromatin remodeling,
cross-talk with histone methyltransferases, acetylases and
deacetylases, and recruitment of methyl binding proteins such
as MeCP2 [18,27]. Similar to other epigenetic modiﬁcations,
DNAMe is now also known to be reversible [28,29]. Non-CpG
methylation has also been found in pluripotent
cells such as embryonic stem cells or early embryos [30,31],
but it is not common in adult somatic tissues [32]. Although
the role of non-CpG island methylation in mammals is largely
unknown, recent studies have shown that it may also promote
gene silencing and contribute to tumorogenesis [33]. DNAMe
regulates important biological processes such as imprinting,
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Figure 1. Chromatin structure and function. Chromatin is made up
of repeating units of nucleosomes consisting of 146 bp DNA wrapped
around dimers of four histone proteins (H2A, H2B, H3, and H4). The
exposed amino-terminal tails of nucleosomal histones are subjected to
post-translational modiﬁcations. Combinatorial effects of histone mod-
iﬁcations and DNAMe regulate the chromatin structure between
transcriptionally silent ‘‘heterochromatin’’ and active ‘‘euchromatin.’’
Enrichment of promoter DNAMe and histone modiﬁcations such as
H3K9me3, H3K27me3, and H4K20me3 promote nucleosome conden-
sation to repress transcription (heterochromatin). On the other hand,
histone modiﬁcations H3 or H4 KAc (H3/H4KAc) and H3K4me promote
open chromatin formation and increase accessibility to the transcrip-
tion machinery, leading to active transcription (euchromatin). Other
histone modiﬁcations such as Ser/Thr phosphorylation, ubiquitination
and SUMOylation, and non-coding RNAs including microRNAs also
regulate chromatin structure and function (not shown). Genome-wide
patterns of DNAMe and histone modiﬁcations are referred to as the
‘‘epigenome.’’ Its response to internal and external signals regulates
gene expression involved in diverse biological processes and disease
conditions. DNAMe, DNA methylomes; KAc, lysine acetylation.
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studied extensively because gene silencing of tumor suppres-
sors and cell-cycle regulators via promoter hypermethylation
has been associated with several cancers. Key epigenetic
therapies based on DNAMe inhibitors have been developed
for cancer [34,35]. However, relatively less is known about the
role of DNAMe in diabetes and its complications.
PTMs at chromatin histones also confer epigenetic changes in
a dynamic fashion. Histone PTMs include lysine acetylation
(KAc), lysine methylation (KMe), arginine methylation, serine/
threonine phosphorylation, SUMOylation, Adenosine dipho-
sphate (ADP)-ribosylation, and ubiquitination (Table 1) [17,25].
In general, the amino acid residues in the exposed amino-
terminal tails of nucleosomal histones are subjected to these
PTMs; some PTMs within globular domain of histones have also
been identiﬁed. Histone PTMs act in concert with each other,
and this ‘‘histone code’’ can dictate gene transcription [17,25].
Histone lysine acetylation (HKAc) and methylation (HKme) are
the best studied and will be discussed in this review. HKAc is
mediated by histone acetyltransferases (HATs) and removed by
histone deacetylases (HDACs). On the other hand, histone lysine
methyltransferases (HMTs) mediate KMe and are erased by
histone lysine demethylases (HDMs). Recently, these enzymes
have been renamed as lysine acetyltransferases, lysine methyl-
transferases, and lysine demethylases, because they can also
modify lysines in nonhistone proteins [37].
Histone modiﬁcations such as H3K9/14 or H4K12/16
acetylation at gene promoters and enhancers are generallyepigenetic marks for active gene transcription. HKAc is
mediated by HATs such as CBP/p300 and SRC-1, which also
act as coactivators. Acetylation of lysine residues in histone
tails neutralizes the positive charge and destabilizes interac-
tions between histones and DNA as well as nucleosome–
nucleosome interactions. In addition, the acetylated residues
act as docking sites for chromatin remodeling proteins, lead-
ing to chromatin relaxation and increased accessibility to the
transcription machinery. HATs are quite nonselective and
acetylate several lysine residues in both histone and non-
histone proteins [17,38]. However, proﬁling approaches such
as chromatin immunoprecipitation followed by next-
generation DNA sequencing (ChIP-Seq) revealed differences
in the genome-wide distribution of individual HATs [39].
Genome-wide approaches also showed that enhancers are
usually associated with CBP and p300 along with histone
lysine monomethylation (H3K4me1) [40–42].
HDACs remove HKAc marks and mediate gene repression.
They are subdivided into four classes, I–IV, depending on their
structure, function, and mode of action. HDACs restore the
positive charge of histone lysines and promote chromatin
condensation, resulting in decreased chromatin access and
reduced rates of transcription. HDACs have multiple func-
tions, which can be attributed to their low substrate speciﬁ-
city. Their actions can be regulated at the level of both gene
expression and promoter-speciﬁc recruitment [43]. Studies in
knockout mice revealed speciﬁc functions of HDACs in vivo,
including embryonic stem cell differentiation and cardiovas-
cular effects [44–46]. The function of HDAC in cancer cells has
been studied extensively, and several HDAC regulators are
being used to treat cancers [35,47].
HKme is very interesting since it can be associated with
either active or repressed genes depending on the modiﬁed
lysine residue (Table 1). Furthermore, lysine residues can be
mono (me1), di (me2), or tri (me3) methylated, adding another
level of complexity. H3K4me, H3K36me, and H3K79me are
usually associated with active promoters and gene bodies,
while H3K9me, H3K27me, and H4K20me promote transcrip-
tion repression. In contrast, demethylation of H3K4me can
inhibit transcription, whereas demethylation of H3K9me,
H3K27me, and H4K20me marks can increase transcription.
HMTs generally contain a SET domain that catalyzes methyl-
transferase activity, whereas demethylation activity in HDMs is
mediated by amine oxidase-like domains or JmjC domains
[25,48]. HMTs and HDMs are highly speciﬁc to the lysine
residue being modiﬁed and also to the extent of methylation,
e.g., SUV39H1 can mediate H3K9me3 but not H3K9me1, Ezh2
mediates H3K27me3, and SET7/9 mediates H3K4me1/me2. On
the other hand, lysine-speciﬁc demethylase 1 (LSD1), the ﬁrst
HDM to be identiﬁed, can erase H3K4me1/me2, while the
JARID1 family of demethylases removes H3K4me3. Jmjd2a can
erase both H3K9me3 and H3K36me3, while Jmjd3 is speciﬁc to
H3K27me3 [17,49] (Table 1). Recent high-throughput proﬁling
of various histone PTMs associated with promoters, enhancers,
and insulators led to the identiﬁcation of such key regulatory
elements genome wide [25,42,50,51]. Transcription start sites
and promoters are enriched with H3K4me3 and H3K9/14Ac,
enhancers with H3K4me1, and gene bodies of actively tran-
scribed genes with H3K36me3. Histone modiﬁcations at
enhancers also confer tissue- and cell-speciﬁc transcription in
conjunction with lineage- or cell-speciﬁc transcription factors
[25,42,52,53]. Histone modiﬁcations can also cross-talk with
each other to regulate gene expression. Thus, H3K27me3 and
Table 1. Histone modiﬁcations and their function in the transcription regulation*
Modiﬁcation Histone Modifying enzyme Proposed function
Acteylation H2A, H3, H4 ATF2, ELP3, GCN5, GTF3C4, HAT1, MORF,
MOZ, p300, PCAF, SRC-1, TAF1, Tip 60
Activation
Deacetylation H2A, H3, H4 HDAC1–HDAC11, SIRT1–SIRT7 Repression
Methylation H1K26, H3K27 Ezh2 Repression
H3K9 ESET, G9a, SUV39H1, SUV39H2, SETDB1 Repression
H3K4 MLL, SET7, SET9, SMYD3 Activation
H3K36 SETD2, NSD1 Activation
H3K79 DOT1L Activation
H4K20 PR-SET7, SUV4-20H1, SUV4-20H2 Repression
H3R17 CARM1 Activation
H4R3 PRMT1 Activation
H3R8 PRMT5 Repression
H4R3 PRMT5 Repression
Demethylation H3K4 LSD1 Repression
H3K4 JARID1A, JARID1B, JARID1C, JARID1D Repression
H3K9 JMJD1A Activation
H3K9/H3K36 JMJD2A, JMJD2B, JMJD2C, JMJD2D Activation/Repression
H3K36 JHDM1A, JHDM1B Repression
H3K27 JMJD3, UTX Activation
Phosphorylation H2AS1, H3S10, H3S28 MSK1 Repression
H3S10 Aurora-B, IKK-a, MSK2, RSK2 Activation
H2AS1, H2AS139, H4S1 ATR, ATM, DNA-PK, CK2, Tel1 DNA repair
Ubiquitylation H2AK119 RING1B Activation/repression
H2BK120 UbcH6 Activation/repression
Biotinylation H2AK9, H2AK13, H3K4,
H3K9, H3K18, H4K12
Biotinidase Activation
n References [17,20,36].
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these bivalent modiﬁcations play important roles in stem cell
differentiation [54]. H3K9Ac and Ser10 phosphorylation gen-
erally inhibit H3K9me to promote gene expression [17]. Cross-
talk between histone PTMs and DNAMe has also been docu-
mented. DNAMe acts in concert with repressive histone mod-
iﬁcations such as H3K9me3 to recruit transcription repressors
and silence gene expression [20,55].
Regulation of histone-modifying enzymes plays a critical
role in gene expression involved in key biological processes
including differentiation, cancer, and diabetes and its compli-
cations [7,8,20,34,36,56,57]. In general, HKme is relatively
more stable compared with other histone modiﬁcations. There-
fore, similar to DNAMe, H3Kme might be involved in the
inheritance of epigenetic signatures to confer transcriptional
memory that lasts long even after the removal of physiological
or pathological signals. Polycomb repressive complex (PRC)
proteins, which mediate the repressive H3K27me3 mark,
remained tightly bound to chromatin during DNA replication,
indicating a potential epigenetic role for such histone marks in
the maintenance of transcription memory or epigenetic trans-
mission [58,59]. Thus, alterations in HKme may contribute to
the metabolic memory of transcription and persistent expres-
sion of pathologic genes implicated in diabetic complications
[8,57]. As discussed earlier, epigenetic marks altered by the
environment can be inherited during both somatic and germ
cell replications [60]. Evidence shows that DNAMe plays an
important role in transgenerationally inherited obesity [61]. In
addition, high-fat diets have been found to promote transge-
nerational transmission of adult-onset metabolic diseases in
mice, suggesting an underlying epigenetic mechanism [62]. In
epigenetic transmission, the role of DNAMe is more apparent
than that of histone modiﬁcations, although evidence also
exists for the latter via PRCs and histone recycling [59,63].
In general, compared to genetic transmission, epigenetictransmission is more complex and needs further investigation,
especially in the ﬁeld of diabetes and its complications.Metabolic memory and diabetes complications
Hyperglycemia has been implicated in the development of
numerous diabetic complications including nephropathy.
Patients with both type 1 diabetes (T1D) and type 2 diabetes
(T2D) continue to be at higher risk for developing complica-
tions even several years after achieving normoglycemia.
This phenomenon of ‘‘metabolic memory’’ was clearly demon-
strated in clinical trials such as the Diabetes Control and
Complications Trial (DCCT) and the follow-up Epidemiology
of Diabetic Interventions and Complications (EDIC) study
[7,8,64]. The DCCT showed that intensive insulin therapy
to attain strict glycemic control in T1D patients led to
much better control of various vascular complications than
conventional therapy [65]. Subsequently, both standard and
intensive treatment DCCT groups were placed on intensive
insulin therapy and followed up long term in EDIC study.
Interestingly, EDIC study showed that those previously
assigned to standard/conventional therapy in DCCT continued
to develop complications, such as nephropathy and retino-
pathy, at signiﬁcantly higher rates than the previous intensive
therapy group in DCCT [66]. Recent reports demonstrate
continued protection and lower rates of cardiac, renal, and
retinal complications; lower blood pressure; more favorable
lipid proﬁles; and reduced long-term risk for impaired glo-
merular ﬁltration rate (GFR) in the former DCCT intensive
therapy group [67–70]. Other clinical trials in T2D patients
also demonstrated that a similar memory phenomenon,
termed ‘‘legacy effect,’’ in those with lower fasting blood
glucose and strict glycemic control resulted in lower rates of
vascular complications [71–73]. These studies clearly
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Figure 2. Diabetic nephropathy and metabolic memory. Signal
transduction mediated by factors associated with the diabetic milieu
(HG, AGEs, growth factors, and oxidized lipids) induces alterations in
epigenetic modiﬁcations (histone PTMs and DNAMe) and changes in
chromatin remodeling. This leads to pathologic gene expression
(inﬂammatory genes and ﬁbrotic genes) in collaboration with key TFs
in monocytes/macrophages, vascular and renal cells. Persistence of
these epigenetic modiﬁcations even after normalizing glucose levels
can play an important role in ‘‘metabolic memory’’ and gene expres-
sion implicated in long-lasting diabetic complications including
nephropathy. AGEs, advanced glycation end products; DNAMe, DNA
methylomes; EC, endothelial cell; GF, growth factor; HG, high glucose;
Ox lipids, oxidized lipids; PTM, post-translational modiﬁcation; TF,
transcription factor.
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fact that a memory of prior exposure to hyperglycemia might
play a signiﬁcant role in the subsequent risk of diabetic
complications including nephropathy. However, mechanisms
of metabolic memory are not clear and remain a major
obstacle in the prevention or treatment of diabetic complica-
tions. As discussed later, recent studies have evaluated a role
for epigenetic mechanisms in metabolic memory.
Several experimental cell culture and animal models have
been developed to understand the mechanisms involved in
metabolic memory. Endothelial cells (ECs) cultured in HG for
short time periods continued to exhibit enhanced oxidative
stress, and proﬁbrotic and inﬂammatory genes even after
return to normal glucose [74–76]. Vascular smooth muscle
cells (VSMC) derived from the aortas of T2D db/db mice
exhibited enhanced proinﬂammatory responses even after
culturing ex vivo for a few weeks [77,78]. In T1D dogs, islet
transplantation performed 12 weeks after the development of
diabetes did not prevent progression to retinopathy, com-
pared to that after 6 weeks [79]. Similarly, in T1D rats,
reinstitution of glycemic control following several weeks of
poor glycemic control did not reverse inﬂammation or pro-
gression to retinopathy and nephropathy [80–83]. Thus, both
clinical and experimental evidences suggest that prior expo-
sure to hyperglycemia can have long-lasting deleterious
effects even after subsequent glycemic control. Other related
factors associated with hyperglycemia and diabetes such as
AGEs may also contribute to metabolic memory, because
AGEs can modify various cellular proteins and enzymes to
cause long-lasting changes in their functions, or can activate
multiple signaling pathways via the receptor for AGE (RAGE)
to induce inﬂammatory genes [84,85]. Furthermore, dyslipi-
demia and insulin resistance associated with T2D may also be
involved. It is likely that these factors acting independently or
cumulatively can lead to changes in epigenetic histone PTMs
and DNAMe in target cells, thus contributing to metabolic
memory (Fig. 2).DNAMe and diabetes complications
DNAMe is the most stable and heritable epigenetic mod-
iﬁcation and is known to play an important role in normal as
well as pathophysiological processes. However, its involve-
ment in diabetes and its complications is less well studied.
Early studies with mouse models showed that regulation of
the Agouti gene by DNAMe plays a key role in the develop-
ment of coat color, diabetes, and obesity. Interestingly, these
studies also demonstrated the inﬂuence of external factors
such as maternal diet on epigenetic processes and the
transgenerational inheritance of DNAMe [60,86]. In a model
of intrauterine growth retardation (IUGR) in rats, it was found
that the development of diabetes was associated with pro-
moter hyper-DNAMe and inhibition of the islet-speciﬁc tran-
scription factor Pdx1 that regulates insulin gene expression in
pancreatic b cells. DNAMe was also found to be related to
downregulation of peroxisome proliferator-activated recep-
tor-gamma coactivator 1a (PGC-1a) and Igf1r in pancreatic
islets and skeletal muscles of T2D animals and patients
[87–89]. PGC-1a downregulation led to the inhibition of
insulin expression and mitochondrial biogenesis [87,88].
Furthermore, in another study, insulin promoter DNAMe in
islets of T2D patients was correlated with lower insulin levelsand elevated HbA1c levels [90]. Another recent study on
monozygotic twins reported a 10% increase in global DNAMe
at Alu repetitive elements in peripheral blood leukocytes,
which showed signiﬁcant correlation with insulin resistance
[91]. Genetic association studies have identiﬁed single nucleo-
tide polymorphisms in the fat mass and obesity-associated
(FTO) gene region with a risk of adiposity. Functional studies
showed that FTO controls feeding behavior and energy expen-
diture [92]. Interestingly, recent studies in T2D patients showed
a small but signiﬁcant decrease in DNAMe at a CpG site in the
ﬁrst intron of the FTO gene [93]. Furthermore, this hypomethy-
lation was also observed in healthy individuals who later
progressed to impaired glucose metabolism. These unique
ﬁndings suggest a correlation between epigenetic DNAMe
variations and predisposition to T2D [93].
Studies, reported to date, investigating kidneys of diabetic
animal models or renal cells treated in vitro with HG have not
demonstrated signiﬁcant changes in DNAMe [94–96]. On the
other hand, whole blood genomic DNA from T1D patients
with DN exhibited differential DNAMe patterns at 19 genes
including UNC13B, relative to those without nephropathy [97].
Interestingly, UNC13B was correlated with DN in genetic
studies, suggesting an association between DNAMe and DN
susceptibility. Several differentially methylated genes were
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compared to patients with chronic kidney disease who did not
progress to ESRD [98]. However, relevance of these ﬁndings to
DN awaits further investigation. It is likely that high-
throughput approaches using genomic DNA and target tissue
biopsies from various clinical cohorts or animal models will
clarify the relationship between DNAMe and diabetic compli-
cations including nephropathy. In this connection, it is note-
worthy that a recent genome-wide proﬁling study using next-
generation sequencing demonstrated signiﬁcant changes in
DNAMe in HG-treated ECs at several genes related to diabetes
and its complications. Reciprocal relations with histone acet-
ylation were also demonstrated [99].Histone modiﬁcations, diabetes complications, and
metabolic memory
Progress in the study of histone PTMs has grown by leaps
and bounds in the ﬁeld of cancer. However, it is still in its
infancy in the ﬁeld of diabetes. Recent studies have shed some
insights into the role of histone modiﬁcations in diabetes,
diabetic complications, and metabolic memory. Histone PTMs
have been implicated in the regulation of insulin expression by
Pdx1 in pancreas. In response to elevated glucose levels, Pdx1
could recruit the HAT coactivator p300 and HMT SET7 to the
insulin promoter, which could promote chromatin relaxation
by increasing H3K9/14Ac and H3K4me1/2, respectively, to
enhance insulin transcription. In contrast, Pdx1 could recruit
HDACs to inhibit insulin expression when glucose levels were
low [100–102]. Interestingly, it was found that IUGR reduces
insulin gene expression by inhibiting Pdx1 expression via
alterations in promoter H3KAc, H3K4me3, and DNAMe in the
offspring [103]. H3K9me2 and H3K4me2, as well as the related
enzymes SETDB1 (H3K9 methyl transferase) and LSD1 (H3K4
demethylase), were reported to play critical roles in adipocyte
differentiation [104]. More direct evidence for histone mod-
iﬁcations in diabetes was suggested in a report, which showed
that mice deﬁcient in Jhdm2a, an H3K9me2 demethylase,
exhibited features of the metabolic syndrome [105]. A recent
genome-wide analysis of histone modiﬁcations revealed a
global snapshot of the islet chromatin, and several islet-
speciﬁc enhancers were identiﬁed. Interestingly, many of
them were located in genetic loci previously associated
with T2D [106]. HDACs were also shown to regulate the
acetylation of several transcription factors involved in adipo-
cyte differentiation, suggesting an important role for non-HKAc
in metabolic disorders [107,108]. However, the role of HDACs
in epigenetic mechanisms involved in diabetes complica-
tions and the potential use of HDAC inhibitors are not well
studied.
Aberrant promoter histone modiﬁcations can be triggered by
HG and other diabetogenic agents to affect adversely the expres-
sion of key target genes associated with complications. Several
studies have examined the role of histone PTMs in the regulation
of inﬂammatory gene expression in ECs, monocytes, VSMCs, and
renal mesangial cells (MCs), all of which are key cell types
involved in diabetes complications [6,57,109–112]. Endothelial
dysfunction, increased oxidant stress, and reduced nitric oxide
are major features of diabetic micro- and macrovascular compli-
cations. In particular, this is associated with decreased levels or
activity of the endothelial nitric oxide (eNOS) enzyme and is
exempliﬁed in studies involving eNOS knockout mice [109].Diabetes reduces NO bioavailability, resulting in increased EC
proliferation, inﬂammatory gene expression, VSMC activation,
and macrophage inﬁltration, which are the key factors in the
development of DN [109,110]. EC-speciﬁc expression of eNOS
involves formation of an open chromatin near the eNOS promoter
marked by increased H3/H4KAc and H4Kme [113,114]. Interest-
ingly, hypoxia, a known mediator of EC dysfunction and a
potential risk factor for DN [115], also inhibits eNOS expression
through reversal of these promoter-speciﬁc histone modiﬁcations
[116]. Other studies have shown that gene expression in mono-
cytes andmacrophages is also regulated by histonemodiﬁcations,
which play key roles in inﬂammation and macrophage polariza-
tion [57,117]. JMJD3, an H3K27me3 demethylase, and HDAC11
appear to play important regulatory roles in these events
[118–120]. HG-induced inﬂammatory gene expression was asso-
ciated with increased promoter H3/H4KAc, and enhanced recruit-
ment of HATs CBP/P300 as well as the proinﬂammatory
transcription factor NF-kB in THP-1 monocytes. Furthermore,
monocytes from diabetic patients exhibited enhanced H3KAc at
the promoters of key inﬂammatory genes, conﬁrming in vivo
relevance [121]. SET7, an H3K4 methyltransferase, was impli-
cated in NF-kB-mediated inﬂammatory gene expression in TNF-
a-treated THP-1 monocytes, and in macrophages from diabetic
mice [122]. Proﬁling studies using ChIP linked to microarrays
(ChIP-on-chip) revealed key differences in the patterns of repres-
sive (H3K9me2) and active (H3K4me2) histone modiﬁcations at
coding regions of HG-regulated genes in THP-1 monocytes, with
in vivo relevance being shown in primary monocytes from
diabetes patients [123]. Furthermore, comparative ChIP-on-chip
epigenome proﬁling of lymphocytes from T1D patients with
those from normal control volunteers revealed signiﬁcant altera-
tions in H3K9me2 at a subset of genes related to T1D and closely
associated with autoimmune functions and inﬂammation [124],
further demonstrating the role of histone modiﬁcations in
diabetes and its complications. Recent ChIP-on-chip studies with
chromosome 6 tiling arrays in monocytes of T1D patients versus
normal control individuals revealed key variations in H3K9Ac at
the upstream enhancer regions of two HLA genes whose single
nucleotide polymorphisms (SNPs) are known to be closely related
with T1D [125], suggesting potential connections between
genetic SNPs and surrounding epigenetic marks in the etiology
of diabetes.
Emerging evidence supports a role for histone modiﬁca-
tions in the regulation of key genes associated with DN. In a
rat model of T2D-induced DN, hyperglycemia in the kidneys
was associated with reduced levels of active chromatin marks
H3KAc and Ser10 phosphorylation at the ﬁbrillin 1 and
collagen type III alpha1 gene promoters [126]. Changes in
global histone modiﬁcations were seen in the kidneys of
uninephrectomized diabetic db/db mice [127]. Furthermore,
HDAC2 activity was increased in kidneys of diabetic animals,
and inhibition of HDAC activity blocked diabetes-induced
ﬁbrotic gene expression [128]. Recently, evidence of epige-
netic mechanisms in HG- and TGF-b1-induced ﬁbrotic gene
expressions in renal MCs was demonstrated for the ﬁrst time
[129]. In these studies, the induction of key proﬁbrotic genes
by HG and its downstream effectors TGF-b1 was associated
with increases in activation marks (H3K4me-1, H3K4me-2,
and H3K4me-3) and decreases in repressive marks (H3K9me-
1 and H3K9me-2) at these gene promoters. Furthermore, HG
and TGF-b1 could induce the expression of SET7, while SET7
gene silencing inhibited TGF-b1-induced expression of ﬁbro-
tic genes. Interestingly, pretreatment with TGF-b1 antibodies
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Figure 3. Role of TGF-b in HG-mediated histone modiﬁcations and
ﬁbrotic gene expression in mesangial cells. HG and its downstream
effector TGF-b promote open chromatin formation at ﬁbrotic gene
promoters through inhibition of repressive marks (H3K9me) and
increasing activation marks (H4Kme) via regulation of HMTs such as
SET7. This leads to an increase in chromatin access to transcription TFs
and in the expression of ﬁbrotic genes such as PAI-1, Col1a1, and CTGF.
These HG-induced alterations in epigenetic mechanisms and proﬁbro-
tic gene expression can be blocked by TGF-b antibodies. Potential role
of other histone modiﬁcations such as H3K9Ac and coactivator HATs is
also shown. HAT, histone acetyltransferase; HG, high glucose; HMT,
histone methyl transferase; TF, transcription factor; TGF-b, transform-
ing growth factor-b1.
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sion and alterations in histone modiﬁcations at their promo-
ters [129]. These results demonstrate the involvement of
histone PTMs in HG- and TGF-b1-induced genes relevant to
DN (Fig. 3).
Role of histone modiﬁcations was also demonstrated in
some nondiabetic kidney diseases. Thus, reports showed that
aldosterone can reverse Dot1a-mediated promoter repressive
H3K79me mark to increase the expression of the epithelial Na
(þ) channel alpha (ENaCa) gene in the renal collecting ducts
[130,131]. In other studies, increased expression of inﬂamma-
tory genes such as MCP-1 in a model of renal ischemic injury
was associated with increased H3K4me3 and recruitment of the
chromatin remodeling enzyme Brahma-related gene-1 (BRG1) at
these gene promoters [132]. Changes in repressive histone PTMs
were associated with collagen III gene expression in aging-
induced nephropathy [133]. Notably, epigenetic mechanisms
have been implicated in renal development and maintenance of
podocyte-differentiated function [134,135]. Together, these data
demonstrate that histone PTMs are involved in the regulation of
genes associated with chronic as well as acute renal injuries, and
even with renal development. However, such candidate-gene-
based approaches can only provide a glimpse of a complex
epigenetic landscape. Genome-wide high-throughput proﬁling
approaches can help provide valuable information about the
state of the epigenome in DN.
Recent studies using cell and animal models have sug-
gested that histone modiﬁcations might be associated with
metabolic memory. In one study, there was enhanced inﬂam-
matory gene expression in VSMCs cultured from T2D db/db
mice for several passages relative to those from genetic
control db/þ mice, and this was associated with persistently
reduced H3K9me3 and occupancy of corresponding methyl
transferase Suv39h1 at inﬂammatory gene promoters [78].
Furthermore, there was also reduced levels of Suv39h1 in the
diabetic db/db VSMCs, which was found to be due to an
increased expression of the microRNAs miR-125b that targets
Suv39h1 [136]. The miR-125b mimics could reduce Suv39h1
levels, upregulate inﬂammatory genes in nondiabetic cells,
and also promote monocyte binding in db/þ VSMCs to induce
a diabetic phenotype. This demonstrates a novel cross-talk
between microRNAs and epigenetic mechanisms in diabetic
vascular inﬂammation and metabolic memory. In another
model of metabolic memory, short-term exposure of ECs to
HG led to persistently increased expression of p65 (active
subunit of NF-kB) and inﬂammatory genes for several days
even after returning to normal glucose. This was associated
with higher promoter levels of H3K4me1 and occupancy of
the corresponding SET7 H3K4 methyl transferase [76,137]. A
key role for oxidant stress in promoting metabolic memory in
ECs was suggested in this and other studies [74,76,99].
Interestingly, in a rat model of diabetic retinopathy and
metabolic memory, retinal ECs exhibited reduced expression
of sod gene that codes for the protective antioxidant protein
superoxide dismutase. This was associated with increased
levels of the repressive mark H4K20me3 and occupancy of the
corresponding methyltransferase Suv420h at the sod gene
promoter, leading to repression of superoxide dismutase [83].
Together, these studies support a key role for histone mod-
iﬁcations in metabolic memory of diabetic vascular complica-
tions that seem to persist despite glycemic control (Fig. 2).
Since renal MCs, tubular epithelial cells, ECs, and podocytes
are also affected by HG and diabetes, similar mechanisms inthese cells in vivo might also contribute to metabolic memory
of DN. Moreover, it has recently been speculated that epige-
netic mechanisms may also regulate hypertension, which is
associated with both diabetic and nondiabetic renal diseases
and can persist across generations [138].Resources and technologies for epigenomics research
in diabetes and its complications
The National Institutes of Health Roadmap Epigenomics
Program is focused on mapping the locations and characterizing
the functions of epigenetic modiﬁcations in normal and diseased
states using numerous cell types and tissues. These epigenomic
maps are being made available to the entire scientiﬁc commu-
nity (http://www.ncbi.nlm.nih.gov/epigenomics) and will be a
tremendous resource for future research. Recent advances in
next-generation sequencing and related technologies as well as
in bioinformatics tools have accelerated epigenomics research
signiﬁcantly [25,139,140]. These include ChIP-on-chip and ChIP-
Seq to study genome-wide patterns of histone modiﬁcations
[25,57,139,141]. DNAMe is traditionally studied using bisulﬁte
conversion of 50-methyl cytosine or approaches to enrich
methylated DNA [142,143]. These are coupled to microarrays
or next-generation DNA-Seq analysis to determine genome-
wide distribution of DNAMe [57,144]. Novel features of the
epigenome, including key regulatory elements/regions, have
been uncovered from the combinatorial and integrative analyses
of genome-wide patterns of histone PTMs and DNAMe along
with transcriptome analyses of gene expression patterns
[25,42,50,51,140,145]. These technologies are gradually being
utilized to decipher the epigenomes of key target cells involved
in diabetes and its complications. Utilization of these genome-
wide proﬁling technologies to study renal biopsies or genomic
DNA from patients with DN or other renal diseases relative to
MA Reddy et al / Epigenetic modiﬁcations and diabetic nephropathy146normal control individuals can yield signiﬁcant information
regarding the epigenome of normal versus diseased kidneys,
which in turn could open the doors for the development of
novel therapeutic opportunities. However, it is also important to
consider conducting such studies on cells or tissues that
manifest the disease, since the epigenome is cell-type speciﬁc.
This could pose a challenge in renal research due to the multi-
cellular nature of the kidney.Summary
Increasing evidence supports the critical role of hypergly-
cemia and downstream mediators such as AGEs, Ang II, and
TGF-b in signaling, molecular, and chromatin-based mechan-
isms in the development of metabolic memory and diabetic
complications (Fig. 2). However, diabetes leads to multiorgan
dysfunction and is associated with several physiological
abnormalities, including insulin resistance and dyslipidemia
(T2D) and autoimmune disorders (T1D). It is further compli-
cated by dietary choices and the lifestyles. Although numer-
ous studies have examined the role of genetic variants in the
pathology of diabetes complications such as DN, very few
candidate loci with functional associations have been uncov-
ered. Given the strong inﬂuence of environmental factors, the
additional role of epigenetics is worth considering. Further-
more, metabolic memory still remains a major obstacle in the
treatment and prevention of diabetes complications. Recent
advances in high-throughput genomic sequencing approaches
should make it feasible to better understand the epigenome
state in diabetes and related complications such as DN.
Importantly, they might reveal key differences in the epigen-
ome between patients who progress to DN and other com-
plications and those who do not. Unlike genetic changes,
epigenetic changes are reversible, which thus provides
a window of opportunity for therapeutic development.
Several epigenetic regulators such as inhibitors of DNAMe,
HDACs, HATs, and DNMTs are already being used for
cancer treatment, and some are being evaluated for vascular
disorders such as restenosis [35,47,146,147]. Recent studies
showing reversal of epigenetic modiﬁcations associated with
islets [103], ECs [113], monocytes [148], and renal cells
[128,129,149] indicate that epigenetic therapy for diabetic
complications is a distinct possibility. Further work in this
rapidly expanding area of research could advance our knowl-
edge of epigenetic mechanisms involved in the pathogenesis
of DN and other diabetic complications, which in turn could
lead to new therapeutic strategies.Conﬂict of interest
None declared.Acknowledgments
The authors gratefully acknowledge funding from the
National Institutes of Health (NIDDK and NHLBI), the Juvenile
Diabetes Research Foundation, and the American Diabetes
Association.References
[1] Ziyadeh FN: Mediators of diabetic renal disease: the case for
TGF-Beta as the major mediator. J Am Soc Nephrol;15(Suppl 1):
S55–S57, 2004
[2] Decleves AE, Sharma K: New pharmacological treatments
for improving renal outcomes in diabetes. Nat Rev Nephrol
6:371–380, 2010
[3] Ramasamy R, Yan SF, Schmidt AM: Receptor for AGE (RAGE):
signaling mechanisms in the pathogenesis of diabetes and its
complications. Ann N Y Acad Sci 1243:88–102, 2011
[4] Brownlee M: The pathobiology of diabetic complications: a
unifying mechanism. Diabetes 54:1615–1625, 2005
[5] Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in
diabetic nephropathy. Kidney Int Suppl 77:S93–S98, 2000
[6] Brosius 3rd FC: New insights into the mechanisms of ﬁbrosis
and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord
9:245–254, 2008
[7] Villeneuve LM, Natarajan R: The role of epigenetics in the
pathology of diabetic complications. Am J Physiol Renal Physiol
299:F14–F25, 2010
[8] Pirola L, Balcerczyk A, Okabe J, El-Osta A: Epigenetic phenom-
ena linked to diabetic complications. Nat Rev Endocrinol 6:
665–675, 2010
[9] Susztak K, Bo¨ttinger EP: Diabetic nephropathy: a frontier for
personalized medicine. J Am Soc Nephrol 17:361–367, 2006
[10] Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM,
Susztak K: Transcriptome analysis of human diabetic kidney
disease. Diabetes 60:2354–2369, 2011
[11] Thomas MC, Groop PH, Tryggvason K: Towards understanding
the inherited susceptibility for nephropathy in diabetes. Curr
Opin Nephrol Hypertens 21:195–202, 2012
[12] Rincon-Choles H, Thameem F, Lehman DM, Arya R, Arar N,
Duggirala R, Stern MP, Abboud HE: Genetic basis of diabetic
nephropathy. Am J Ther 12:555–561, 2005
[13] Jirtle RL, Skinner MK: Environmental epigenomics and disease
susceptibility. Nat Rev Genet 8:253–262, 2007
[14] Ling C, Groop L: Epigenetics: a molecular link between environ-
mental factors and type 2 diabetes. Diabetes 58:2718–2725, 2009
[15] Goldberg AD, Allis CD, Bernstein E: Epigenetics: a landscape
takes shape. Cell 128:635–638, 2007
[16] Bonasio R, Tu S, Reinberg D: Molecular signals of epigenetic
states. Science 330:612–616, 2010
[17] Kouzarides T: Chromatin modiﬁcations and their function. Cell
128:693–705, 2007
[18] Miranda TB, Jones PA: DNA methylation: the nuts and bolts of
repression. J Cell Physiol 213:384–390, 2007
[19] Natoli G: Maintaining cell identity through global control of
genomic organization. Immunity 33:12–24, 2010
[20] Portela A, Esteller M: Epigenetic modiﬁcations and human
disease. Nat Biotechnol 28:1057–1068, 2010
[21] Feil R, Fraga MF: Epigenetics and the environment: emerging
patterns and implications. Nat Rev Genet 13:97–109, 2011
[22] Woroniecki R, Gaikwad AB, Susztak K: Fetal environment,
epigenetics, and pediatric renal disease. Pediatr Nephrol 26:705
711, 2011
[23] Fagerudd J, Forsblom C, Pettersson-Fernholm K, Saraheimo M,
Wade´n J, Ro¨nnback M, Rosenga˚rd-Ba¨rlund M, Bjo¨rkesten CG,
Thorn L, Wessman M, Groop PH: Low birth weight does not
increase the risk of nephropathy in Finnish type 1 diabetic
patients. Nephrol Dial Transplant 21:2159–2165, 2006
[24] Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ:
Crystal structure of the nucleosome core particle at 2.8 A
resolution. Nature 389:251–260, 1997
[25] Zhou VW, Goren A, Bernstein BE: Charting histone modiﬁca-
tions and the functional organization of mammalian genomes.
Nat Rev Genet 12:7–18, 2011
Kidney Res Clin Pract 31 (2012) 139–150 147[26] Bernstein BE, Meissner A, Lander ES: The mammalian epigen-
ome. Cell 128:669–681, 2007
[27] Sansom OJ, Maddison K, Clarke AR: Mechanisms of disease:
methyl-binding domain proteins as potential therapeutic targets
in cancer. Nat Clin Pract Oncol 4:305–315, 2007
[28] Wu SC, Zhang Y: Active DNA demethylation: many roads lead
to Rome. Nat Rev Mol Cell Biol 11:607–620, 2010
[29] Chen ZX, Riggs AD: DNA methylation and demethylation in
mammals. J Biol Chem 286:18347–18353, 2011
[30] Haines TR, Rodenhiser DI, Ainsworth PJ: Allele-speciﬁc non-CpG
methylation of the Nf1 gene during early mouse development.
Dev Biol 240:585–598, 2001
[31] Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP,
Jaenisch R: Non-CpG methylation is prevalent in embryonic
stem cells and may be mediated by DNA methyltransferase 3a.
Proc Natl Acad Sci U S A 97:5237–5242, 2000
[32] Law JA, Jacobsen SE: Establishing, maintaining and modifying
DNA methylation patterns in plants and animals. Nat Rev Genet
11:204–220, 2010
[33] Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G: DNA
methylation directly silences genes with non-CpG island pro-
moters and establishes a nucleosome occupied promoter. Hum
Mol Genet 20:4299–4310, 2011
[34] Jones PA, Baylin SB: The epigenomics of cancer. Cell 128:
683–692, 2007
[35] Kelly TK, De Carvalho DD, Jones PA: Epigenetic modiﬁcations as
therapeutic targets. Nat Biotechnol 28:1069–1078, 2010
[36] Bhaumik SR, Smith E, Shilatifard A: Covalent modiﬁcations of
histones during development and disease pathogenesis. Nat
Struct Mol Biol 14:1008–1016, 2007
[37] Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T,
Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Work-
man J, Zhang Y: New nomenclature for chromatin-modifying
enzymes. Cell 131:633–636, 2007
[38] Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu
Rev Biochem 70:81–120, 2001
[39] Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y,
van Galen M, van Dam H, van Ommen GJ, den Dunnen JT,
Zantema A, t Hoen PA: Genome-wide assessment of differential
roles for p300 and CBP in transcription regulation. Nucleic Acids
Res 38:5396–5408, 2010
[40] Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J,
Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S,
Markenscoff-Papadimitriou E, Kuhl D, Bito H, Worley PF, Krei-
man G, Greenberg ME: Widespread transcription at neuronal
activity-regulated enhancers. Nature 465:182–187, 2010
[41] Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick
I, Shoukry M, Wright C, Chen F, Afzal V, Ren B, Rubin EM,
Pennacchio LA: ChIP-seq accurately predicts tissue-speciﬁc
activity of enhancers. Nature 457:854–858, 2009
[42] Jin F, Li Y, Ren B, Natarajan R: Enhancers: multi-dimensional
signal integrators. Transcription 2:226–230, 2011
[43] Yang XJ, Seto E: HATs and HDACs: from structure, function and
regulation to novel strategies for therapy and prevention.
Oncogene 26:5310–5318, 2007
[44] Dovey OM, Foster CT, Cowley SM: Histone deacetylase 1 (HDAC1),
but not HDAC2, controls embryonic stem cell differentiation. Proc
Natl Acad Sci U S A 107:8242–8247, 2010
[45] Margariti A, Zampetaki A, Xiao Q, Zhou B, Karamariti E,
Martin D, Yin X, Mayr M, Li H, Zhang Z, De Falco E, Hu Y, Cockerill
G, Xu Q, Zeng L: Histone deacetylase 7 controls endothelial cell
growth through modulation of beta-catenin. Circ Res 106:
1202–1211, 2010
[46] Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T,
Goettlicher M, Noppinger PR, Wurst W, Ferrari VA, Abrams CS,
Gruber PJ, Epstein JA: Hdac2 regulates the cardiac hyper-
trophic response by modulating Gsk3 beta activity. Nat Med 13:
324–331, 2007[47] Selvi BR, Mohankrishna DV, Ostwal YB, Kundu TK: Small molecule
modulators of histone acetylation and methylation: a disease
perspective. Biochim Biophys Acta 810–828:2010, 1799
[48] Shi Y: Histone lysine demethylases: emerging roles in
development, physiology and disease. Nat Rev Genet 8:829–833,
2007
[49] Shi Y, Whetstine JR: Dynamic regulation of histone lysine
methylation by demethylases. Mol Cell 25:1–14, 2007
[50] Hon GC, Hawkins RD, Ren B: Predictive chromatin signatures in
the mammalian genome. Hum Mol Genet 18:R195–R201, 2009
[51] Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei
G, Chepelev I, Zhao K: High-resolution proﬁling of histone
methylations in the human genome. Cell 129:823–837, 2007
[52] Jin F, Li Y, Ren B, Natarajan R: PU.1 and C/EBP(alpha) synergis-
tically program distinct response to NF-kappaB activation
through establishing monocyte speciﬁc enhancers. Proc Natl
Acad Sci U S A 108:5290–5295, 2011
[53] Taberlay PC, Kelly TK, Liu CC, You JS, De Carvalho DD, Miranda
TB, Zhou XJ, Liang G, Jones PA: Polycomb-repressed genes have
permissive enhancers that initiate reprogramming. Cell 147:
1283–1294, 2011
[54] Herz HM, Nakanishi S, Shilatifard A: The curious case of
bivalent marks. Dev Cell 17:301–303, 2009
[55] Cedar H, Bergman Y: Linking DNA methylation and histone
modiﬁcation: patterns and paradigms. Nat Rev Genet 10:
295–304, 2009
[56] Giacco F, Brownlee M: Oxidative stress and diabetic complica-
tions. Circ Res 107:1058–1070, 2010
[57] Reddy MA, Natarajan R: Epigenetic mechanisms in diabetic
vascular complications. Cardiovasc Res 90:421–429, 2011
[58] Bantignies F, Cavalli G: Cellular memory and dynamic regula-
tion of polycomb group proteins. Curr Opin Cell Biol 18:275
283, 2006
[59] Francis NJ, Follmer NE, Simon MD, Aghia G, Butler JD: Polycomb
proteins remain bound to chromatin and DNA during DNA
replication in vitro. Cell 137:110–122, 2009
[60] Morgan HD, Sutherland HG, Martin DI, Whitelaw E: Epigenetic
inheritance at the agouti locus in the mouse. Nat Genet
23:314–318, 1999
[61] Waterland RA, Travisano M, Tahiliani KG, Rached MT, Mirza S:
Methyl donor supplementation prevents transgenerational
ampliﬁcation of obesity. Int J Obes (Lond) 32:1373–1379, 2008
[62] Pentinat T, Ramon-Krauel M, Cebria J, Diaz R, Jimenez-Chillaron JC:
Transgenerational inheritance of glucose intolerance in a mouse
model of neonatal overnutrition. Endocrinology 151:5617–5623,
2010
[63] Groth A, Corpet A, Cook AJ, Roche D, Bartek J, Lukas J, Almouzni
G: Regulation of replication fork progression through histone
supply and demand. Science 318:1928–1931, 2007
[64] Ceriello A: Hypothesis: the ‘‘metabolic memory‘‘, the new challenge
of diabetes. Diabetes Res Clin Pract;86(Suppl 1):S2–S6, 2009
[65] Writing Team for the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications
Research Group: Effect of intensive therapy on the microvascular
complications of type 1 diabetes mellitus. JAMA 287:2563–2569,
2002
[66] Writing Team for the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications
Research Group: Sustained effect of intensive treatment of type
1 diabetes mellitus on development and progression of diabetic
nephropathy: the Epidemiology of Diabetes Interventions and
Complications (EDIC) study. JAMA 290:2159–2167, 2003
[67] Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW,
Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH:
Effects of prior intensive insulin therapy on cardiac autonomic
nervous system function in type 1 diabetes mellitus: the
Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications study (DCCT/EDIC).
Circulation 119:2886–2893, 2009
MA Reddy et al / Epigenetic modiﬁcations and diabetic nephropathy148[68] de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW,
Zinman B: Intensive diabetes therapy and glomerular ﬁltration rate
in type 1 diabetes. N Engl J Med 365:2366–2376, 2011
[69] White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth
DP, Hubbard LD, Lachin JM, Nathan DM: Prolonged effect of
intensive therapy on the risk of retinopathy complications
in patients with type 1 diabetes mellitus: 10 years after the
Diabetes Control and Complications Trial. Arch Ophthalmol
126:1707–1715, 2008
[70] de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes
MW, Sun W, Zinman B, Brunzell JD, White NH, Danis RP, Davis
MD, Hainsworth D, Hubbard LD, Nathan DM: Long-term renal
outcomes of patients with type 1 diabetes mellitus and micro-
albuminuria: an analysis of the Diabetes Control and Complica-
tions Trial/Epidemiology of Diabetes Interventions and
Complications cohort. Arch Intern Med 171:412–420, 2011
[71] Colagiuri S, Cull CA, Holman RR: Are lower fasting plasma
glucose levels at diagnosis of type 2 diabetes associated with
improved outcomes? U.K. prospective diabetes study 61 Dia-
betes Care 25:1410–1417, 2002
[72] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl
J Med 359:1577–1589, 2008
[73] Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M,
Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S,
Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A,
Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive
blood glucose control and vascular outcomes in patients with type
2 diabetes. N Engl J Med 358:2560–2572, 2008
[74] Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R,
Boemi M, Giugliano D: Oscillating glucose is more deleterious
to endothelial function and oxidative stress than mean glucose
in normal and type 2 diabetic patients. Diabetes 57:1349–1354,
2008
[75] Roy S, Sala R, Cagliero E, Lorenzi M: Overexpression of ﬁbro-
nectin induced by diabetes or high glucose: phenomenon with
a memory. Proc Natl Acad Sci U S A 87:404–408, 1990
[76] El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG,
Cooper ME, Brownlee M: Transient high glucose causes persis-
tent epigenetic changes and altered gene expression during
subsequent normoglycemia. J Exp Med 205:2409–2417, 2008
[77] Li SL, Reddy MA, Cai Q, Meng L, Yuan H, Lanting L, Natarajan R:
Enhanced proatherogenic responses in macrophages and vas-
cular smooth muscle cells derived from diabetic db/db mice.
Diabetes 55:2611–2619, 2006
[78] Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L,
Natarajan R: Epigenetic histone H3 lysine 9 methylation in
metabolic memory and inﬂammatory phenotype of vascular
smooth muscle cells in diabetes. Proc Natl Acad Sci U S A
105:9047–9052, 2008
[79] Engerman RL, Kern TS: Progression of incipient diabetic retinopathy
during good glycemic control. Diabetes 36:808–812, 1987
[80] Chan PS, Kanwar M, Kowluru RA: Resistance of retinal inﬂam-
matory mediators to suppress after reinstitution of good
glycemic control: novel mechanism for metabolic memory.
J Diabetes Complications 24:55–63, 2010
[81] Kowluru RA: Effect of reinstitution of good glycemic control on
retinal oxidative stress and nitrative stress in diabetic rats.
Diabetes 52:818–823, 2003
[82] Kowluru RA, Abbas SN, Odenbach S: Reversal of hyperglycemia
and diabetic nephropathy: effect of reinstitution of good
metabolic control on oxidative stress in the kidney of diabetic
rats. J Diabetes Complications 18:282–288, 2004
[83] Zhong Q, Kowluru RA: Epigenetic changes in mitochondrial
superoxide dismutase in the retina and the development of
diabetic retinopathy. Diabetes 60:1304–1313, 2011
[84] Yan SF, Ramasamy R, Bucciarelli LG, Wendt T, Lee LK, Hudson
BI, Stern DM, Lalla E, Yan DU, Rong S, Naka LL, Schmidt Y: AM:RAGE and its ligands: a lasting memory in diabetic complica-
tions? Diab Vasc Dis Res 1:10–20, 2004
[85] Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease:
advanced glycation end-products and their receptor in inﬂam-
mation and diabetes complications. Nat Clin Pract Endocrinol
Metab 4:285–293, 2008
[86] Dolinoy DC, Jirtle RL: Environmental epigenomics in human
health and disease. Environ Mol Mutagen 49:4–8, 2008
[87] Ling C, Del Guerra S, Lupi R, Ro¨nn T, Granhall C, Luthman H,
Masiello P, Marchetti P, Groop L, Del Prato S: Epigenetic
regulation of PPARGC1A in human type 2 diabetic islets and
effect on insulin secretion. Diabetologia 51:615–622, 2008
[88] Barres R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, Krook A,
Zierath JR: Non-CpG methylation of the PGC-1alpha promoter
through DNMT3B controls mitochondrial density. Cell Metab
10:189–198, 2009
[89] Nikoshkov A, Sunkari V, Savu O, Forsberg E, Catrina SB, Brismar
K: Epigenetic DNA methylation in the promoters of the Igf1
receptor and insulin receptor genes in db/db mice. Epigenetics
6:405–409, 2011
[90] Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L,
Wollheim CB, Nitert MD, Ling C: Insulin promoter DNA methy-
lation correlates negatively with insulin gene expression and
positively with HbA(1c) levels in human pancreatic islets.
Diabetologia 54:360–367, 2011
[91] Zhao J, Goldberg J, Bremner JD, Vaccarino V: Global DNA
methylation is associated with insulin resistance: a monozy-
gotic twin study. Diabetes 61:542–546, 2012
[92] Fawcett KA, Barroso I: The genetics of obesity: FTO leads the
way. Trends Genet 26:266–274, 2010
[93] Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B,
Wainstein J, Friedlander Y, Levy-Lahad E, Glaser B, Hellman A:
Genome-wide survey reveals predisposing diabetes type 2-
related DNA methylation variations in human peripheral blood.
Hum Mol Genet 21:371–383, 2012
[94] Brennan EP, Ehrich M, Brazil DP, Crean JK, Murphy M, Sadlier
DM, Martin F, Godson C, van den Boom D, Maxwell AP, Savage
DA: DNA methylation proﬁling in cell models of diabetic
nephropathy. Epigenetics 5:396–401, 2010
[95] Williams KT, Garrow TA, Schalinske KL: Type I diabetes leads to
tissue-speciﬁc DNA hypomethylation in male rats. J Nutr
138:2064–2069, 2008
[96] Williams KT, Schalinske KL: Tissue-speciﬁc alterations of
methyl group metabolism and DNA hypermethylation in the
Zucker (type 2) diabetic fatty rat. Diabetes Metab Res Rev
28:123–131, 2011
[97] Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S,
Savage DA: Genome-wide DNA methylation analysis for dia-
betic nephropathy in type 1 diabetes mellitus. BMC Med
Genomics 3:33–42, 2010
[98] Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J, Siraj ES,
Madaio M: DNA methylation proﬁling identiﬁes epigenetic
differences between diabetes patients with ESRD and diabetes
patients without nephropathy. Epigenetics 6:20–28, 2011
[99] Pirola L, Balcerczyk A, Tothill RW, Haviv I, Kaspi A, Lunke S,
Ziemann M, Karagiannis T, Tonna S, Kowalczyk A, Beresford-
Smith B, Macintyre G, Kelong M, Hongyu Z, Zhu J, El-Osta A:
Genome-wide analysis distinguishes hyperglycemia regulated
epigenetic signatures of primary vascular cells. Genome Res
21:1601–1615, 2011
[100] Chakrabarti SK, Francis J, Ziesmann SM, Garmey JC, Mirmira RG:
Covalent histone modiﬁcations underlie the developmental
regulation of insulin gene transcription in pancreatic beta cells.
J Biol Chem 278:23617–23623, 2003
[101] Francis J, Babu DA, Deering TG, Chakrabarti SK, Garmey JC,
Evans-Molina C, Taylor DG, Mirmira RG: Role of chromatin
accessibility in the occupancy and transcription of the insulin
gene by the pancreatic and duodenal homeobox factor 1. Mol
Endocrinol 20:3133–3145, 2006
Kidney Res Clin Pract 31 (2012) 139–150 149[102] Francis J, Chakrabarti SK, Garmey JC, Mirmira RG: Pdx-1 links
histone H3-Lys-4 methylation to RNA polymerase II elongation
during activation of insulin transcription. J Biol Chem
280:36244–36253, 2005
[103] Pinney SE, Jaeckle Santos LJ, Han Y, Stoffers DA,
Simmons RA: Exendin-4 increases histone acetylase activity
and reverses epigenetic modiﬁcations that silence Pdx1 in the
intrauterine growth retarded rat. Diabetologia 54:2606–2614,
2011
[104] Musri MM, Carmona MC, Hanzu FA, Kaliman P, Gomis R,
Parrizas M: Histone demethylase LSD1 regulates adipogenesis.
J Biol Chem 285:30034–30041, 2010
[105] Tateishi K, Okada Y, Kallin EM, Zhang Y: Role of Jhdm2a in
regulating metabolic gene expression and obesity resistance.
Nature 458:757–761, 2009
[106] Stitzel ML, Sethupathy P, Pearson DS, Chines PS, Song L, Erdos
MR, Welch R, Parker SC, Boyle AP, Scott LJ, Margulies EH,
Boehnke M, Furey TS, Crawford GE, Collins FS: Global epige-
nomic analysis of primary human pancreatic islets provides
insights into type 2 diabetes susceptibility loci. Cell Metab
12:443–455, 2010
[107] Gray SG, De Meyts P: Role of histone and transcription factor
acetylation in diabetes pathogenesis. Diabetes Metab Res Rev
21:416–433, 2005
[108] Haigis MC, Sinclair DA: Mammalian sirtuins: biological insights
and disease relevance. Annu Rev Pathol 5:253–295, 2010
[109] Nakagawa T, Segal M, Croker B, Johnson RJ: A breakthrough in
diabetic nephropathy: the role of endothelial dysfunction.
Nephrol Dial Transplant 22:2775–2777, 2007
[110] Wang Y, Harris DC: Macrophages in renal disease. J Am Soc
Nephrol 22:21–27, 2011
[111] Matouk CC, Marsden PA: Epigenetic regulation of vascular
endothelial gene expression. Circ Res 102:873–887, 2008
[112] Reddy MA, Natarajan R: Epigenetics in diabetic kidney disease.
J Am Soc Nephrol 22:2182–2185, 2011
[113] Fish JE, Matouk CC, Rachlis A, Lin S, Tai SC, D’Abreo C, Marsden PA:
The expression of endothelial nitric-oxide synthase is controlled
by a cell-speciﬁc histone code. J Biol Chem 280:24824–24838,
2005
[114] Chen W, Bacanamwo M, Harrison DG: Activation of p300
histone acetyltransferase activity is an early endothelial
response to laminar shear stress and is essential for stimulation
of endothelial nitric-oxide synthase mRNA transcription. J Biol
Chem 283:16293–16298, 2008
[115] Nangaku M: Chronic hypoxia and tubulointerstitial injury: a
ﬁnal common pathway to end-stage renal failure. J Am Soc
Nephrol 17:17–25, 2006
[116] Fish JE, Yan MS, Matouk St CC, Bernard R, Ho JJ, Gavryushova A,
Srivastava D, Marsden PA: Hypoxic repression of endothelial
nitric-oxide synthase transcription is coupled with eviction of
promoter histones. J Biol Chem 285:810–826, 2010
[117] Takeuch O, Akira S: Epigenetic control of macrophage polariza-
tion. Eur J Immunol 41:2490–2493, 2011
[118] De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G,
Natoli G: The histone H3 lysine-27 demethylase Jmjd3 links
inﬂammation to inhibition of polycomb-mediated gene silen-
cing. Cell 130:1083–1094, 2007
[119] Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y,
Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh T, Honma
K, Matsuyama T, Yui K, Tsujimura T, Standley DM, Nakanishi K,
Nakai K, Akira S: The Jmjd3-Irf4 axis regulates M2 macrophage
polarization and host responses against helminth infection. Nat
immunol 11:936–944, 2010
[120] Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M,
Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E,
Sotomayor EM: The histone deacetylase HDAC11 regulates the
expression of interleukin 10 and immune tolerance. Nat Immu-
nol 10:92–100, 2009[121] Miao F, Gonzalo IG, Lanting L, Natarajan R: In vivo chromatin
remodeling events leading to inﬂammatory gene transcrip-
tion under diabetic conditions. J Biol Chem 279:18091–18097,
2004
[122] Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, Ren
B, Natarajan R: Role of the histone H3 lysine 4 methyltransfer-
ase, SET7/9, in the regulation of NF-kappaB-dependent inﬂam-
matory genes. Relevance to diabetes and inﬂammation. J Biol
Chem 283:26771–26781, 2008
[123] Miao F, Wu X, Zhang L, Yuan YC, Riggs AD, Natarajan R:
Genome-wide analysis of histone lysine methylation variations
caused by diabetic conditions in human monocytes. J Biol Chem
282:13854–13863, 2007
[124] Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R:
Lymphocytes from patients with type 1 diabetes display a
distinct proﬁle of chromatin histone H3 lysine 9 dimethylation:
an epigenetic study in diabetes. Diabetes 57:3189–3198,
2008
[125] Miao F, Chen Z, Zhang L, Liu Z, Wu X, Yuan YC, Natarajan R: Proﬁles
of epigenetic histone post-translational modiﬁcations at type 1
diabetes susceptible genes. J Biol Chem 287:16335–16345, 2012: .
[125 143].
[126] Gaikwad AB, Gupta J, Tikoo K: Epigenetic changes and alteration of
Fbn1 and Col3A1 gene expression under hyperglycaemic and
hyperinsulinaemic conditions. Biochem J 432:333–341, 2010
[127] Sayyed SG, Gaikwad AB, Lichtnekert J, Kulkarni O, Eulberg D,
Klussmann S, Tikoo K, Anders HJ: Progressive glomerulosclero-
sis in type 2 diabetes is associated with renal histone H3K9 and
H3K23 acetylation, H3K4 dimethylation and phosphorylation at
serine 10. Nephrol Dial Transplant 25:1811–1817, 2010
[128] Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB: Histone
deacetylase-2 is a key regulator of diabetes- and transforming
growth factor-beta1-induced renal injury. Am J Physiol Renal
Physiol 297:F729–F739, 2009
[129] Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R:
Epigenetic histone methylation modulates ﬁbrotic gene expres-
sion. J Am Soc Nephrol 21:2069–2080, 2010
[130] Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC:
Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethy-
lation and repression of ENaCalpha in an aldosterone-sensitive
manner. J Biol Chem 281:18059–18068, 2006
[131] Zhang W, Xia X, Reisenauer MR, Rieg T, Lang F, Kuhl D, Vallon V,
Kone BC: Aldosterone-induced Sgk1 relieves Dot1a-Af9-
mediated transcriptional repression of epithelial Naþ channel
alpha. J Clin Invest 117:773–783, 2007
[132] Naito M, Zager RA, Bomsztyk K: BRG1 increases transcription of
proinﬂammatory genes in renal ischemia. J Am Soc Nephrol
20:1787–1796, 2009
[133] Abrass CK, Hansen K, Popov V, Denisenko O: Alterations in
chromatin are associated with increases in collagen III expression
in aging nephropathy. Am J Physiol Renal Physiol 300:F531–F539,
2011
[134] Lefevre GM, Patel SR, Kim D, Tessarollo L, Dressler GR: Altering
a histone H3K4 methylation pathway in glomerular podocytes
promotes a chronic disease phenotype. PLoS Genet 6:e1001142,
2010
[135] Dressler GR: Epigenetics, development, and the kidney. J Am Soc
Nephrol 19:2060–2067, 2008
[136] Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L,
Natarajan R: Enhanced levels of microRNA-125b in vascular
smooth muscle cells of diabetic db/db mice lead to increased
inﬂammatory gene expression by targeting the histone methyl-
transferase Suv39h1. Diabetes 59:2904–2915, 2010
[137] Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK,
Calkin AC, Brownlee M, Cooper ME, El-Osta A: Hyperglycemia
induces a dynamic cooperativity of histone methylase and
demethylase enzymes associated with gene-activating epigenetic
marks that coexist on the lysine tail. Diabetes 58:1229–1236, 2009
MA Reddy et al / Epigenetic modiﬁcations and diabetic nephropathy150[138] Cowley Jr AW, Nadeau JH, Baccarelli A, Berecek K, Fornage M,
Gibbons GH, Harrison DG, Liang M, Nathanielsz PW, O’Connor
DT, Ordovas J, Peng W, Soares MB, Szyf M, Tolunay HE, Wood
KC, Zhao K, Galis ZS: Report of the national heart, lung, and
blood institute working group on epigenetics and hypertension.
Hypertension 59:899–905, 2012
[139] Schones DE, Zhao K: Genome-wide approaches to studying
chromatin modiﬁcations. Nat Rev Genet 9:179–191, 2008
[140] Maunakea AK, Chepelev I, Zhao K: Epigenome mapping in
normal and disease States. Circ Res 107:327–339, 2010
[141] Metzker ML: Sequencing technologies—the next generation.
Nat Rev Genet 11:31–46, 2010
[142] Mohn F, Weber M, Schu¨beler D, Roloff TC: Methylated DNA
immunoprecipitation (MeDIP). Methods Mol Biol 507:55–64, 2009
[143] Rauch TA, Pfeifer GP: DNA methylation proﬁling using the
methylated-CpG island recovery assay (MIRA). Methods 52:
213–217, 2010[144] Laird PW: Principles and challenges of genomewide DNA
methylation analysis. Nat Rev Genet 11:191–203, 2010
[145] Hawkins RD, Hon GC, Ren B: Next-generation genomics: an
integrative approach. Nat Rev Genet 11:476–486, 2010
[146] Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH,
Jukema JW: Epigenetic histone acetylation modiﬁers in vascular
remodelling: new targets for therapy in cardiovascular disease.
Eur Heart J 30:266–277, 2009
[147] Natarajan R: Drugs targeting epigenetic histone acetylation in
vascular smooth muscle cells for restenosis and atherosclerosis.
Arterioscler Thromb Vasc Biol 31:725–727, 2011
[148] Yun JM, Jialal I, Devaraj S: Epigenetic regulation of high glucose-
induced proinﬂammatory cytokine production in monocytes by
curcumin. J Nutr Biochem 22:450–458, 2011: . [148].
[149] Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S: Curcumin prevents
diabetes-associated abnormalities in the kidneys by inhibiting p300
and nuclear factor-kappaB. Nutrition 25:964–972, 2009
